Bivalirudin use-an update after the Matrix trial

Bivalirudin use-an update after the Matrix trial

This is the presentation I had at the CCIF meeting at Guiyang, China, April 2015.

Which is the current role of Bivalirudin in ACS patients, nowadays? Did the Matrix trial change the scenario, or created more confusion on the matter?

 

FinalBivalirudin presentation China

BVS Survey 2014

This is the PPTX presentation of the BVS survey 2014, as presented at the BVS Advisory Board of Abbott in March 2015. This is a spontaneous survey dedicated to BVS Expert Users, and I shared this research with M. Valgimigli, Bern.

It is of some interest to see how Experts felt this technology by mid-2014, and a publication in the International Journal of Cardiology followed. Another Survey was depicted in 2015 and we are currently analyzing its results.

I am thus wishing you all a happy New Year!!

BVS survey2

Letter in response to the Editorial of JACC Int

Letter in response to the Editorial of JACC Int

A few weeks ago, our study on DCB in native coronary vessels left with a dissection was published in JACC Int, and we had the honor of receiving a dedicated Editorial from 2 experts on the field: R Byrne and M Joner. Their conclusion was different from ours from several points of view, so we deemed necessary to underline further aspects and we wrote a Letter to the Editor.

Effect of drug-coated balloons in native coronary artery disease left with a dissection. J Am Coll Cardiol Intv. 2015

This important paper from our group was just published in JACC Interventions, and commented on TCTMD.

Please see comments here:

http://www.tctmd.com/show.aspx?id=133232&utm_source=2015-11-30-tctmd-newsletter&utm_medium=email&utm_campaign=tctmd-newsletter